

Paper No. 16
Filed: May 1, 2014

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BIODELIVERY SCIENCES INTERNATIONAL, INC.
Petitioner

v.

RB PHARMACEUTICALS LIMITED
Patent Owner.

Case IPR2014-00325
Patent 8,475,832

**PATENT OWNER SECOND AMENDED MANDATORY NOTICE
INFORMATION UNDER 37 C.F.R. § 42.8(a)(2)**

I. REAL PARTY-IN-INTEREST

The real parties-in-interest are RB Pharmaceuticals Limited (Patent Owner), the sole owner of U.S. Patent No. 8,475,832 ('832 patent), and Reckitt Benckiser Pharmaceuticals, Inc. (RBP), the exclusive licensee of the '832 patent in the U.S. Both companies are subsidiaries of the same parent company, Reckitt Benckiser Group plc. Patent Owner's address is 103-105 Bath Road, Slough, UK. RBP's address is 10710 Midlothian Turnpike, Suite 430, Richmond, Virginia.

Pursuant to a written agreement with RBP, MonoSol Rx, LLC (MonoSol) has exclusive manufacturing rights under the '832 patent and therefore is an implied, exclusive licensee thereunder. MonoSol is also the original assignee of the patent, and the named inventors were, and in some cases remain, MonoSol employees. To the extent these facts are sufficient to render MonoSol a real party-in-interest, Patent Owner also identifies MonoSol under 37 CFR § 42.8(b)(1). MonoSol's address is 30 Technology Drive, Warren, New Jersey.

II. RELATED MATTERS

The '832 patent has been asserted against Petitioner in *Reckitt Benckiser Pharmaceuticals, Inc., RB Pharmaceuticals Limited, and MonoSol Rx, LLC. v. BioDelivery Sciences International, Inc.*, E.D.N.C. Civil Action No. 5:13-cv-760-BO. The '832 patent has also been asserted in *Reckitt Benckiser Pharmaceuticals,*

Inc., RB Pharmaceuticals Limited, and MonoSol Rx, LLC. v. Par Pharmaceutical, Inc., and IntelGenx Technologies, Corp., D. Del. Civil Action No. 13-1461-RGA; *Reckitt Benckiser Pharmaceuticals, Inc., RB Pharmaceuticals Limited, and MonoSol Rx, LLC. v. Watson Laboratories, Inc.*, D. Del. Civil Action No. 13-1674-RGA; *Reckitt Benckiser Pharmaceuticals, Inc., RB Pharmaceuticals Limited, and MonoSol Rx, LLC. v. Alvogen Pine Brook, Inc.*, D. Del. Civil Action No. 13-2003-RGA; and *Reckitt Benckiser Pharmaceuticals, Inc., RB Pharmaceuticals Limited, and MonoSol Rx, LLC. v. Par Pharmaceutical, Inc., and IntelGenx Technologies, Corp.*, D. Del. Civil Action No. 14-422-RGA.

U.S. Application No. 13/964,975, which is a continuation of U.S. Application No. 13/923,749 (now abandoned), which was a continuation of U.S. Application No. 12/537,571 ('571 application, now the '832 patent), is pending. U.S. Application No. 12/537,580, which was filed at the same time as, and shares a portion of the specification of, the '571 application is pending and may also potentially be affected by a decision in the proceeding herein.

III. LEAD AND BACKUP COUNSEL AND SERVICE INFORMATION

Lead Counsel:

James M. Bollinger, Esq.
Troutman Sanders LLP
The Chrysler Building
405 Lexington Avenue
New York, NY 10174
Tel: (212) 704-6113
Fax: (212) 704-5954
Email: james.bollinger@troutmansanders.com
Registration No. 32,555

Backup Counsel:

Daniel A. Ladow, Esq.
Troutman Sanders LLP
The Chrysler Building
405 Lexington Avenue
New York, NY 10174
Tel: (212) 704-6218
Fax: (212) 704-5929
Email: daniel.ladow@troutmansanders.com
Pro hac vice

Counsel consent to electronic service at their email addresses.

IV. PATENT OWNER PRELIMINARY RESPONSE

Patent Owner filed a preliminary response on April 30, 2014.

Dated: May 1, 2014

/James M. Bollinger/
James M. Bollinger
Reg. No. 32,555

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of the foregoing Patent Owner Second Amended Mandatory Notice Information Under 37 C.F.R. § 42.8(a)(2) was served electronically via email on May 1, 2014, on attorneys for Petitioner:

Danielle L. Herritt
Kia L. Freeman
McCARTER & ENGLISH, LLP
265 Franklin Street
Boston, MA 02110

dherritt@mccarter.com
IPR832@mccarter.com

Dated: May 1, 2014

/James M. Bollinger/
James M. Bollinger
Reg. No. 32,555